News
Calling all income investors! Two dividend kinds deserve your attention in 2025: Colgate-Palmolive (NYSE:CL) and Emerson ...
JP Morgan analyst Andrea Teixeira maintained Colgate-Palmolive with an Overweight rating and raised the price target from $95 ...
Colgate-Palmolive posted a higher profit in the first quarter but lowered 2025 earnings guidance due to tariffs.
We look at Colgate-Palmolive Company's Q1 results, market challenges, and tariff impacts. Read to see if the CL stock is ...
The owner of skin care brand Sanex is also expecting a price hike on sold goods as a result of US President Donald Trump’s ...
Colgate-Palmolive on Friday reported better-than-expected first-quarter results and lifted its full-year sales outlook, ...
Organic sales rose 1.4% during the quarter, with pricing up 1.5% and volume down 0.1%. The impact of FX was a negative 4.4% ...
April 25 (Reuters) - Colgate-Palmolive (CL.N), opens new tab reported quarterly results that beat Wall Street estimates and raised its annual sales forecast on Friday, banking on moderate price ...
John Faucher; Chief Investor Relations Officer and Executive Vice President, M&A; Colgate-Palmolive Co Noel Wallace; Chairman of the Board, President, Chief Executive Officer; Colgate-Palmolive Co ...
Colgate-Palmolive alum Elaine Paik will step into the skincare brand’s top financial seat and will also lead the company’s ...
Colgate-Palmolive (CL) reported $4.91 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 3%. EPS of $0.91 for the same period compares to $0.86 a year ago.
The latest price target for Colgate-Palmolive (NYSE:CL) was reported by UBS on April 17, 2025. The analyst firm set a price target for $109.00 expecting CL to rise to within 12 months (a possible ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results